INmune Bio (NASDAQ:INMB - Get Free Report) had its price target raised by stock analysts at Scotiabank from $22.00 to $23.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm presently has a "sector outperform" rating on the stock. Scotiabank's target price would indicate a potential upside of 151.64% from the stock's current price.
INMB has been the topic of several other research reports. RODMAN&RENSHAW upgraded INmune Bio to a "strong-buy" rating in a report on Tuesday, January 28th. Rodman & Renshaw began coverage on INmune Bio in a report on Tuesday, January 28th. They issued a "buy" rating and a $23.00 target price on the stock. Finally, Alliance Global Partners began coverage on INmune Bio in a report on Monday, October 21st. They issued a "buy" rating and a $20.00 target price on the stock. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $22.80.
Get Our Latest Analysis on INMB
INmune Bio Stock Down 1.7 %
NASDAQ:INMB traded down $0.16 on Tuesday, hitting $9.14. The stock had a trading volume of 245,498 shares, compared to its average volume of 504,241. The business's fifty day moving average is $6.44 and its 200 day moving average is $6.11. The company has a market cap of $202.63 million, a PE ratio of -4.20 and a beta of 1.87. INmune Bio has a 52 week low of $4.32 and a 52 week high of $14.49.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of INMB. Financial Advocates Investment Management lifted its holdings in shares of INmune Bio by 17.4% in the third quarter. Financial Advocates Investment Management now owns 13,500 shares of the company's stock valued at $73,000 after purchasing an additional 2,000 shares in the last quarter. Praetorian PR LLC lifted its holdings in INmune Bio by 61.0% during the third quarter. Praetorian PR LLC now owns 780,800 shares of the company's stock worth $4,209,000 after acquiring an additional 295,800 shares during the period. State Street Corp lifted its holdings in INmune Bio by 35.1% during the third quarter. State Street Corp now owns 226,428 shares of the company's stock worth $1,220,000 after acquiring an additional 58,838 shares during the period. Jane Street Group LLC bought a new stake in INmune Bio during the third quarter worth $79,000. Finally, XTX Topco Ltd bought a new stake in INmune Bio during the third quarter worth $249,000. Institutional investors own 12.72% of the company's stock.
INmune Bio Company Profile
(
Get Free Report)
INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
Featured Articles
Before you consider INmune Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and INmune Bio wasn't on the list.
While INmune Bio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
